Gilead Sciences said its experimental antiviral drug remdesivir helped improve outcomes for patients with COVID-19, suggesting it worked better when given earlier in the course of infection, reports Reuters.
Gilead provided information on two clinical trials underway. The company said a study being conducted by the National Institute of Allergy and Infectious Diseases met its main goal in helping patients with COVID-19, the disease caused by the novel coronavirus.
More detailed information on that study will be provided at a later date, Gilead said.
[link url="https://www.reuters.com/article/us-health-coronavirus-gilead-remdesivir/gilead-says-remdesivir-shows-improvement-in-covid-19-patients-when-used-early-idUSKBN22B1T9"]Reuters report[/link]